17.03.2011 • NewsCelesioFritz OesterleHaniel

Fritz Oesterle to Leave Celesio in June

Celesios Chief Executive Fritz Oesterle will step down in June.
Celesio's Chief Executive Fritz Oesterle will step down in June.

Celesio's Chief Executive Fritz Oesterle, who has had a strained relationship with the company's majority shareholder, is stepping down after more than 12 years in office.

"Fritz Oesterle ... will retire from his office in amicable mutual agreement with the supervisory board as of June 30," the German drugs distributor and pharmacy operator said in a statement on Wednesday.

Celesio's dealings with the German industrial and retail conglomerate Haniel, which holds just over 50 percent in Celesio, have not been easy.

Celesio's management has been frustrated by receiving mixed messages from Haniel about how much in Celesio it plans to hold in the future, sources close to Celesio have said.

Talks between Shanghai Pharmaceutical and Haniel over the possibility of the Chinese company acquiring a large stake in Celesio have cooled, sources told Reuters last month.

In 2009, Oesterle ruffled the feathers of Haniel's management by the way he managed the acquisition of Brazilian drugs wholesaler Panpharma, but subsequently managed to smooth over the rift.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.